Cancer Survival Study After Heart Inflammation from Immunotherapy
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Injuries & trauma clinical trials.
This research tracks outcomes for cancer patients who developed heart inflammation (myocarditis) while receiving immune checkpoint inhibitor therapy. By studying survival patterns, researchers hope to better understand how to manage this serious side effect and improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been treated with at least one immune checkpoint inhibitor (a type of immunotherapy for cancer)
- You have been diagnosed with myocarditis (inflammation of the heart muscle) that was possibly, probably, or definitely caused by your immunotherapy
- Medical records showing when your myocarditis started are available
- Your medical team can track your health outcomes over time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
This study follows people who had a heart-related side effect from immunotherapy and are now ready for rehab. It aims to better understand recovery and guide treatment.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
This study looks at whether certain immunotherapy drugs (nivolumab, pembrolizumab, or ipilimumab) affect the heart in people with skin cancer. You will have special heart imaging to check for any early signs of heart problems.
Hear when a new Immune Checkpoint Inhibitor-associated Myocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.